The odds of its new drug getting established in the U.K. are now much lower.Everyone knows that big pharma companies like Eli Lilly (LLY 0.32%) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't the only group the companies need appease before shareholders can see a return.And sometimes, those other groups can throw a wrench into the works, damping long-term growth. As of now, it's looking like Lilly might have stumbled into a pi ...